Engineered immune cells for leukemia that has not responded to treatment
Part of Blood & lymphatic, Cancer, Skin clinical trials.
This trial tests a new type of cell therapy for people with a fast-growing blood cancer (AML or BPDCN) that has not improved with standard treatments. The therapy uses specially modified immune cells (called CAR T cells) to target and kill cancer cells. It may be an option for those who have run out of other treatment choices.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have AML or BPDCN that is active and has not been cured by at least two prior treatments, or has come back after a stem cell transplant.
- You must be between 6 months and 75 years old.
- Your leukemia cells must have specific markers (called CD123 and CD33) that the therapy targets.
- You must have a family member or unrelated donor who can give cells for the therapy, and you must be able to receive a stem cell transplant after.
- You must be healthy enough for the treatment, with acceptable heart, lung, liver, and kidney function, and a life expectancy of more than 12 weeks.
- You must not have active infections like HIV, hepatitis B or C, or other serious uncontrolled medical conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment that uses your own immune cells, modified in the lab to find and attack leukemia cells. It's for people with AML that has come back or hasn't responded to standard treatment, and it may be followed by a stem cell transplant to help prevent the cancer from returning.
This trial tests a new type of CAR-T cell therapy that targets two proteins on leukemia cells (called CLL1 and CD33). The goal is to help people with acute myeloid leukemia that has relapsed or not responded to standard treatments.
This early-phase study tests a lab-made immune therapy (CD123 CAR T cells) for children and young adults up to age 21 whose cancer has come back or didn’t respond to treatment. The goal is to see if these CAR T cells can find and attack cancer cells that carry a marker called CD123.
This study tests a new treatment that uses your own immune cells (called CAR-T cells) to fight leukemia, followed by a stem cell transplant to help rebuild your immune system. It is designed for people with acute myeloid leukemia (AML) that has not gone away or has come back after standard treatment.
This trial tests a new immune cell therapy for people with acute myeloid leukemia (AML) that has come back or not gone away after treatment. The therapy uses your own cells, modified to target cancer cells, and may help when other treatments haven't worked.
This trial tests a new approach for people with acute myeloid leukemia (AML) that has not gotten better with standard treatments. First, you receive modified stem cells, then specially designed immune cells (CAR T cells) that target a protein called CD33 on leukemia cells. The goal is to see if this combination can safely help your body fight the leukemia.
Hear when a new AML (Acute Myeloid Leukemia) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.